Table 1.
Vaccine antigen | Antigen type | Increase in percentage mortality at 48 h after feeding (%) | Reference |
---|---|---|---|
Whole SME | Native | 24.0* | [20] |
IEX-Group-4 | Native | 23.5* | [20] |
Deg-VIT-1 | Recombinant | 21.9* | [20] |
Der g 11 | Recombinant | 20.1* | Present study |
IEX-Group-1 | Native | 19.5* | [20] |
Deg-HGP-1 | Recombinant | 18.9* | [20] |
Deg-PUF-1 | Recombinant | 18.4* | [20] |
Der g 10 | Recombinant | 16.5* | Present study |
Deg-CPR-1 | Recombinant | 14.5 | [20] |
IEX-Group-3 | Native | 13.0* | [20] |
Deg-SRP-1 | Recombinant | 12.3* | [20] |
IEX-Group-5 | Native | 11.4* | [20] |
PBS-soluble | Native | 10.1* | [36] |
Dg-CatD-1 | Recombinant | 6.9* | [39] |
Deg-ASP-1 | Recombinant | 5.6 | [20] |
Dg-HRF | Recombinant | 4.1* | [37] |
Deg-GPD-1 | Recombinant | 4.1 | [20] |
Deg-PUF-3 | Recombinant | 3.5 | [20] |
Dg-CatL-1 | Recombinant | 2.6* | [39] |
Membrane associated | Native | 2.2 | [36] |
Deg-PUF-2 | Recombinant | 0.6 | [20] |
Urea- soluble | Native | 0.2 | [36] |
Integral membrane | Native | -1.5 | [36] |
IEX-Group-2 | Native | -4.2 | [20] |
Deg-SRP-2 | Recombinant | -8.2 | [20] |
*Statistically significant difference (P < 0.05) between mortalities in the control and antigen test groups in the original study